These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 30946043)
41. Rapid resolution of suicidal behavior and depression with single low-dose ketamine intravenous push even after 6 months of follow-up. Aligeti S; Quinones M; Salazar R J Clin Psychopharmacol; 2014 Aug; 34(4):533-5. PubMed ID: 24875072 [No Abstract] [Full Text] [Related]
42. Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion. Pennybaker SJ; Niciu MJ; Luckenbaugh DA; Zarate CA J Affect Disord; 2017 Jan; 208():560-566. PubMed ID: 27839782 [TBL] [Abstract][Full Text] [Related]
43. Intravenous ketamine for treatment-resistant major depressive disorder. Covvey JR; Crawford AN; Lowe DK Ann Pharmacother; 2012 Jan; 46(1):117-23. PubMed ID: 22190250 [TBL] [Abstract][Full Text] [Related]
44. Two case studies of patients with major depressive disorder given low-dose (subanesthetic) ketamine infusions. Correll GE; Futter GE Pain Med; 2006; 7(1):92-5. PubMed ID: 16533209 [No Abstract] [Full Text] [Related]
45. Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study. Zisook S; Lesser IM; Lebowitz B; Rush AJ; Kallenberg G; Wisniewski SR; Nierenberg AA; Fava M; Luther JF; Morris DW; Trivedi MH J Clin Psychiatry; 2011 Oct; 72(10):1322-32. PubMed ID: 22075098 [TBL] [Abstract][Full Text] [Related]
46. Low-dose ketamine for treatment resistant depression in an academic clinical practice setting. Feifel D; Malcolm B; Boggie D; Lee K J Affect Disord; 2017 Oct; 221():283-288. PubMed ID: 28666206 [TBL] [Abstract][Full Text] [Related]
47. Measures of suicidality in phase 3 clinical trials of levomilnacipran ER in adults with major depressive disorder. Thase ME; Gommoll C; Chen C; Kramer K; Khan A; Durgam S CNS Spectr; 2017 Dec; 22(6):475-483. PubMed ID: 28521846 [TBL] [Abstract][Full Text] [Related]
48. Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression. Liebrenz M; Stohler R; Borgeat A World J Biol Psychiatry; 2009; 10(4 Pt 2):640-3. PubMed ID: 17853274 [TBL] [Abstract][Full Text] [Related]
49. Ketamine as a rapid-acting agent for suicidal ideation: A meta-analysis. Bartoli F; Riboldi I; Crocamo C; Di Brita C; Clerici M; Carrà G Neurosci Biobehav Rev; 2017 Jun; 77():232-236. PubMed ID: 28342764 [TBL] [Abstract][Full Text] [Related]
50. Ketamine for suicidal ideation: heed lessons from opiate epidemic. Breen E BMJ; 2022 Mar; 376():o597. PubMed ID: 35260394 [No Abstract] [Full Text] [Related]
51. Intravenous ketamine "burst" for refractory depression in a patient with advanced cancer. Stefanczyk-Sapieha L; Oneschuk D; Demas M J Palliat Med; 2008 Nov; 11(9):1268-71. PubMed ID: 19021495 [TBL] [Abstract][Full Text] [Related]
52. Ketamine-an update on its clinical uses and abuses. Xu J; Lei H CNS Neurosci Ther; 2014 Dec; 20(12):1015-20. PubMed ID: 25417928 [TBL] [Abstract][Full Text] [Related]
54. The use of ketamine as an antidepressant: a systematic review and meta-analysis. Coyle CM; Laws KR Hum Psychopharmacol; 2015 May; 30(3):152-63. PubMed ID: 25847818 [TBL] [Abstract][Full Text] [Related]
55. Ketamine versus midazolam in bipolar depression with suicidal thoughts: A pilot midazolam-controlled randomized clinical trial. Grunebaum MF; Ellis SP; Keilp JG; Moitra VK; Cooper TB; Marver JE; Burke AK; Milak MS; Sublette ME; Oquendo MA; Mann JJ Bipolar Disord; 2017 May; 19(3):176-183. PubMed ID: 28452409 [TBL] [Abstract][Full Text] [Related]
56. Time Course and Predictors of Suicidal Ideation During Citalopram Treatment in the STAR*D Trial. Coughlin CG; Jakubovski E; Bloch MH J Clin Psychiatry; 2016 Oct; 77(10):e1262-e1269. PubMed ID: 27631142 [TBL] [Abstract][Full Text] [Related]
57. Short-term ketamine administration in treatment-resistant depression patients: focus on adverse effects on the central nervous system. Włodarczyk A; Cubała WJ; Szarmach J; Małyszko A; Wiglusz MS Psychiatr Danub; 2019 Sep; 31(Suppl 3):530-533. PubMed ID: 31488786 [TBL] [Abstract][Full Text] [Related]
58. Disentangling the association of depression on the anti-fatigue effects of ketamine. Saligan LN; Farmer C; Ballard ED; Kadriu B; Zarate CA J Affect Disord; 2019 Feb; 244():42-45. PubMed ID: 30312839 [TBL] [Abstract][Full Text] [Related]
59. Oral ketamine augmentation for chronic suicidality in treatment-resistant depression. De Gioannis A; De Leo D Aust N Z J Psychiatry; 2014 Jul; 48(7):686. PubMed ID: 24452289 [No Abstract] [Full Text] [Related]